CGON
HealthcareCG Oncology, Inc.
$40.04
$-1.75 (-4.19%)
Jan 5, 2026
Price History (1Y)
Analysis
CG Oncology, Inc. operates in the healthcare sector within the biotechnology industry. With a market capitalization of $3.23 billion and 113 employees, the company is a significant player in its field. Financially, CG Oncology's profitability is severely impacted, with gross margins at 0.0%, operating margins at -3069.0%, and profit margins also at 0.0%. The company generates returns of -24.7% on equity and -17.6% on assets. Its balance sheet reveals $680.26 million in cash and only $7.24 million in debt, resulting in a debt-to-equity ratio of 1.05. CG Oncology's valuation metrics include a negative forward P/E ratio of -15.74 and an EV/EBITDA of -15.03. The company has experienced significant revenue growth, with a year-over-year increase of 3774.4%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About CG Oncology, Inc.
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Visit website →Key Statistics
- Market Cap
- $3.23B
- P/E Ratio
- N/A
- 52-Week High
- $46.01
- 52-Week Low
- $14.80
- Avg Volume
- 909.86K
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 113